Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Veracyte's core tests are Decipher and Afirma. Both of these tests are producing double-digit growth with improving margins. I think that bodes well for VCYT's potential as a long-term cash flow machine. Moreover, VCYT's Prosigna and TrueMRD add more long-term upside, which management hasn't yet included in its recent 2026 testing-revenue guidance.
Veracyte (VCYT) is evolving into a self-funded cancer diagnostic platform, leveraging clinical evidence, specialist relationships, and reimbursement infrastructure. Q2 2026 results showed 15% revenue growth, 23% adjusted EBITDA growth, and 29.2% EBITDA margin, with robust cash generation and no funded debt. Prosigna and TrueMRD launches offer significant upside, as 2026 guidance excludes their contributions, while Decipher and Afirma drive core growth and margin expansion.
Veracyte, Inc. (VCYT) Q2 2026 Earnings Call Transcript
Veracyte (VCYT) came out with quarterly earnings of $0.54 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.44 per share a year ago.
Grew total revenue to $150.3 million and testing revenue to $145.7 million , representing increases of 15% and 19% year-over-year, respectively Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif.
Veracyte's core tests are Decipher and Afirma. Both of these tests are producing double-digit growth with improving margins. I think that bodes well for VCYT's potential as a long-term cash flow machine. Moreover, VCYT's Prosigna and TrueMRD add more long-term upside, which management hasn't yet included in its recent 2026 testing-revenue guidance.
Veracyte (VCYT) is evolving into a self-funded cancer diagnostic platform, leveraging clinical evidence, specialist relationships, and reimbursement infrastructure. Q2 2026 results showed 15% revenue growth, 23% adjusted EBITDA growth, and 29.2% EBITDA margin, with robust cash generation and no funded debt. Prosigna and TrueMRD launches offer significant upside, as 2026 guidance excludes their contributions, while Decipher and Afirma drive core growth and margin expansion.
Veracyte, Inc. (VCYT) Q2 2026 Earnings Call Transcript
Veracyte (VCYT) came out with quarterly earnings of $0.54 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.44 per share a year ago.
Grew total revenue to $150.3 million and testing revenue to $145.7 million , representing increases of 15% and 19% year-over-year, respectively Conference call and webcast today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif.
SOUTH SAN FRANCISCO, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will be participating in the following investor conferences:
First Trust Advisors LP lifted its stake in shares of Veracyte, Inc. (NASDAQ: VCYT) by 64.9% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,117,046 shares of the biotechnology company's stock after acquiring an additional 833,543 shares during the
Veracyte (VCYT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FBT surged 51.6% in one year but carries higher risk and costs. VHT offers broader diversification at a fraction of the expense ratio.
Fifth Third Bancorp boosted its position in shares of Veracyte, Inc. (NASDAQ: VCYT) by 10,285.2% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 52,549 shares of the biotechnology company's stock after purchasing an additional 52,043 shares during the period. Fifth Third
FBT delivered 52.4% returns over one year but with deeper drawdowns, while XLV's diversified approach offers lower costs and steadier performance.
Amova Asset Management Americas Inc. lessened its stake in shares of Veracyte, Inc. (NASDAQ: VCYT) by 16.9% in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,045,047 shares of the biotechnology company's stock after selling 212,851 shares during the quarter. Amova
Artisan Mid Cap Fund portfolio generated strong absolute returns and outpaced the Russell Midcap® Growth Index. Within IT, several semiconductor holdings produced exceptional returns, with multiple positions rising more than 100% during the period. During the quarter, we initiated new positions in Entegris, Modine Manufacturing and C.H. Robinson Worldwide.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the second quarter 2026 after the close of market on Thursday, July 30, 2026. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company's website and will b.
Veracyte (VCYT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Chief Accounting Officer Jonathan Wygant sold 24,000 shares on May 22, 2026, generating a transaction value of ~$1.09 million at an average price around $45.40 per share. This transaction reduced direct holdings by 34.57%, leaving 45,434 shares directly owned post-sale.
VCYT's 117% stock surge is driven by durable growth plans, Afirma demand, TrueMRD progress, international IVD efforts and a debt-free balance sheet.
A director of Veracyte reported selling 3,729 shares for a transaction value of approximately $197K on June 18, 2026. This disposition represented roughly 20% of Karin Eastham's direct common stock holdings, reducing direct ownership to 15,097 shares.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Explore how these two healthcare ETFs differ in diversification, sector focus, and portfolio concentration-key factors shaping their long-term investor appeal.
Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock?
Veracyte, Inc. (VCYT) Discusses ASCO Findings From OPTIMA and ENZAMET Phase III Trials in Breast and Prostate Cancer Transcript
On the heels of the landmark [url="]OPTIMA trial[/url] readout presented at the ASCO Annual Meeting, Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostic
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #BreastCancer--Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.
[url="]Veracyte, Inc.[/url] (Nasdaq: VCYT), a leading cancer diagnostics company, today announced results from the [url="]ENZAMET trial[/url] presented at the
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #ASCO26--ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #ASCO26--OPTIMA Trial Delivers Practice-Changing Evidence that Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemo.
Veracyte is evolving into a multi-cancer clinical decision-making platform, leveraging evidence, payer coverage, and workflow integration for durable growth. Q1 2026 results showed 21% revenue growth, expanding gross margins (up to 76% non-GAAP), and strong operating leverage, with raised 2026 guidance and robust cash generation. Medicare coverage for TrueMRD in muscle-invasive bladder cancer and the upcoming Prosigna LDT launch in breast cancer expand VCYT's addressable market and reinforce its evidence-driven moat.
VCYT gains from strong Afirma and Decipher test growth, but macro pressures and competition pose risks. See what may shape its next move.
Today we feature studies to be presented at the year's most important cancer conference, the upcoming American Society of Clinical Oncology meeting in Chicago, all with the potential to be practice-changing.
VCYT jumps 65.8% in a year as Afirma and Decipher volumes surge, guidance lifts, and TrueMRD nears launch with $439M cash and no debt.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that it will host a conference call and webcast on Monday, June 1, 2026 at 8:30 a.m. ET to discuss data from two significant phase III clinical trials using its Prosigna Breast and Decipher Prostate tests that will be presented at the 2026 ASCO Annual Meeting. This includes results from the OPTIMA and ENZAMET trials. Professor Iain Macpherson, one of the principal i.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #ASCO26--OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that the company will be participating in the following investor conferences. William Blair 46th Annual Growth Stock Conference – Chicago, IL Presentation on Tuesday, June 2nd at 2:00 p.m. Central Time 2026 Jefferies Global Healthcare Conference – New York, NY Fireside chat on Thursday, June 4th at 8:10 a.m. Eastern Time Live audio webcasts of the company's presentations will be available by visiting Ver.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT #BladderCancer--Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer.
On May 13, 2026, Veracyte Inc (VCYT) shares fell 3.3%, bringing the current price to $38.26. The stock has experienced a 52-week range of $22.61 to $50.71, show
